Placement of an Expandable Metallic Stent Improves the Efficacy of Chemoradiotherapy for Pancreatic Cancer with Malignant Portal Vein Stenosis or Obstruction
Background: Advanced or recurrent pancreatic cancer can sometimes cause obstruction or stenosis of the portal vein (PV), resulting in various symptoms of portal hypertension (PH), such as ascites, pancytopenia, hemorrhagic tendencies and liver dysfunction. We placed an expandable metallic stent into...
Saved in:
Published in | Anticancer research Vol. 29; no. 8; pp. 3329 - 3335 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Attiki
International Institute of Anticancer Research
01.08.2009
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background: Advanced or recurrent pancreatic cancer can sometimes cause obstruction or stenosis of the portal vein (PV), resulting
in various symptoms of portal hypertension (PH), such as ascites, pancytopenia, hemorrhagic tendencies and liver dysfunction.
We placed an expandable metallic stent into the PV to improve PH-associated complications and liver function. The placement
of the PV stent was beneficial for administering chemotherapeutic agents and radiotherapy (RT) safely, and resulted in an
improved response rate (RR) and survival. Patients and Methods: In the present study, 14 patients with malignant portal obstruction
due to advanced or recurrent pancreatic cancer received PV stent placement to manage their PH-associated symptoms. After a
mini-laparotomy at the ileocecal region, the ileocecal vein was cut and an expandable metallic stent (6-8 mm in diameter and
6-8 cm in length) was inserted into the PV under image roentgenography. After placement of the PV stent, the patients received
anti-coagulation treatment with heparin and biaspirin for 1-3 months. All patients received chemotherapy with UFT, cyclophosphamide
(CPA) and gemcitabine (GEM), and 11 patients also received RT. Results: The RR was 43% (3 complete (CR), 3 partial (PR), 3
stable disease (SD), and 5 progressive disease (PD)), and the mean survival times (MST) after the initiation of therapy or
placement of the PV-stent were 12.6 and 9.5 months, respectively, while the 1-year survival rates were 54.5% and 35.1%, respectively.
In the 3 CR patients, 2 died of carcinomatous ascites 13 and 21 months later, and 1 is still disease free. In the PR and SD
patients, pain and PH-associated symptoms such as ascites and hyperglycemia were also improved. Conclusion: The placement
of a PV stent is beneficial for improving PH-associated symptoms as well as facilitating chemo-RT and the efficacy of therapy. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0250-7005 1791-7530 |